HBK Sorce Advisory’s Oragenics OGEN Stock Holding History

HBK Sorce Advisory’s Portfolio OGEN Stock Details OGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-454	Closed	-$2.86K	–	617
2025 Q1	$2.86K	Hold	454	–	–	﹤0.01%	594
2024 Q4	$5.03K	Buy	+454	New	+$4.65K	﹤0.01%	577

Other funds holding OGEN

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

LWM

Lionsbridge Wealth Management Jacksonville Beach, Florida $99.5M AUM 25.42% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

HBK Sorce Advisory's OGEN Position: Q2 2025 in Review

HBK Sorce Advisory sold out of Oragenics (OGEN) in Q2 2025, closing a stake of 454 shares — an estimated $2.86K sold.

HBK Sorce Advisory first reported a position in OGEN in Q4 2024 and held it in 2 quarters. The position peaked at $5.03K in Q4 2024. 18 funds tracked by Wall St. Rank hold OGEN as of Q2 2025.

HBK Sorce Advisory reported no remaining Oragenics position as of Q2 2025 after selling out during the quarter.
HBK Sorce Advisory sold 454 Oragenics shares in Q2 2025, an estimated $2.86K.
HBK Sorce Advisory first reported a position in Oragenics in Q4 2024 and held it in 2 quarters.
HBK Sorce Advisory's Oragenics position peaked at $5.03K in Q4 2024.
18 funds tracked by Wall St. Rank held Oragenics as of Q2 2025.

Based on HBK Sorce Advisory's 13F filing for Q2 2025, filed 4 Aug 2025.